Dividend Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 1,824,366,726 shares[2]. - The company has not issued any bonus shares during the dividend distribution[2]. - The company distributed a cash dividend of 3 RMB per 10 shares, totaling 547,310,017.80 RMB, which represents 100% of the distributable profit[97]. - The total distributable profit for the year was 2,133,013,349.87 RMB, after accounting for the net profit of 598,509,071.39 RMB and the statutory surplus reserve[97]. - The cash dividend policy remained unchanged during the reporting period, ensuring compliance with the company's articles of association and shareholder resolutions[96]. Financial Performance - The company's operating revenue for 2022 was ¥4,516,979,408.06, representing a 1.82% increase compared to ¥4,436,200,125.41 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥1,076,265,283.57, a decrease of 17.14% from ¥1,298,897,164.35 in 2021[12]. - The total revenue for the company in 2022 was ¥4,516,979,408.06, representing a year-on-year growth of 1.82%[24]. - The operating profit decreased by 16.03% year-on-year to ¥1,424,462,549.65[24]. - The basic earnings per share for 2022 was ¥0.5897, a decline of 17.33% compared to ¥0.7133 in 2021[12]. Assets and Liabilities - The total assets at the end of 2022 were ¥14,740,966,166.50, an increase of 27.77% from ¥11,537,237,136.45 at the end of 2021[12]. - The total liabilities were reported at CNY 8,200,000,000, with current liabilities accounting for a significant portion[162]. - The equity attributable to the parent company reached CNY 10,398,562,106.26, compared to CNY 8,336,955,957.18 in the previous year, marking a significant increase of approximately 25%[163]. Research and Development - The company is conducting clinical trials for seven monoclonal antibody products, with several already in advanced stages, indicating a robust pipeline for future revenue growth[22]. - The company is committed to independent research and development, having established multiple laboratories to support the development of blood products, vaccines, and gene engineering products[65]. - Research and development expenses rose by 24.08% to ¥314,700,635.01 from ¥253,634,720.97 in the previous year[46]. Market Position and Strategy - The company operates 32 plasma collection stations, with a total plasma collection volume exceeding 1,100 tons in 2022, indicating a strong position in the industry[20]. - The blood products industry is experiencing increased concentration, with the top five foreign companies holding 80%-85% of the market share, suggesting a trend towards consolidation in the domestic market as well[19]. - The company is actively pursuing market expansion and innovation in its product offerings to enhance its competitive position[24]. Governance and Management - The company has confirmed that all board members attended the meeting to review the annual report[2]. - The board of directors is composed in accordance with legal requirements, with established committees that enhance operational efficiency and governance[71]. - The company has implemented a transparent performance evaluation and incentive mechanism for its senior management, aiming to attract and retain top talent[71]. Environmental Compliance - Hualan Biological has complied with various environmental protection laws and has not faced any administrative penalties for violations during the reporting period[106]. - The company has established a wastewater treatment facility with a capacity of 900 m³/d, ensuring compliance with the GB21907-2008 standards for wastewater discharge[112]. - The company has not reported any pollution incidents or disputes during the reporting period[106]. Shareholder Information - The total number of shares held by the chairman, An Kang, is 3,265,274.06 shares, with no changes during the reporting period[76]. - The largest shareholder, Ankang, holds 17.90% of the shares, totaling 326.53 million[140]. - The number of shareholders holding ordinary shares increased to 207,982 by the end of the reporting period[140]. Internal Controls - The company has established a comprehensive internal control system, with no significant deficiencies identified in financial reporting controls[100]. - The internal control audit report confirmed that 100% of the assets and revenue of the evaluated units were included in the consolidated financial statements[102]. - The company continues to focus on enhancing internal audit supervision and improving the effectiveness of internal controls[100].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 2.35 billion, representing an increase of 82.32% compared to the same period last year[11]. - The net profit attributable to shareholders of the listed company was approximately CNY 582.99 million, an increase of 27.49% year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 462.63 million, reflecting a year-on-year increase of 16.86%[11]. - The basic earnings per share for the period was CNY 0.3198, up 27.51% from the previous year[11]. - The total operating revenue for the first half of 2022 reached CNY 2,349,403,299.73, a significant increase of 82.5% compared to CNY 1,288,596,915.49 in the same period of 2021[74]. - Net profit for the first half of 2022 was CNY 679,971,840.18, representing a 51.1% increase from CNY 449,873,838.47 in the first half of 2021[75]. - The company's operating profit for the first half of 2022 was CNY 789,237,411.61, up from CNY 534,006,824.60 in the previous year, indicating a growth of 47.7%[75]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately CNY 14.62 billion, an increase of 26.69% compared to the end of the previous year[11]. - The company's total assets at the end of the first half of 2022 were ¥9,064,045,319.60, reflecting a growth from the previous year[84]. - The company's total liabilities reached CNY 2.98 billion, up from CNY 2.47 billion, reflecting an increase of about 20.5%[72]. - The total equity attributable to shareholders increased to CNY 9.90 billion from CNY 8.34 billion, a growth of approximately 18.7%[72]. Cash Flow - The net cash flow from operating activities was approximately CNY 11.73 million, a significant decrease of 98.42% compared to the previous year[11]. - Cash flow from operating activities generated a net amount of CNY 11,732,435.25, significantly lower than CNY 740,410,409.15 in the previous year[80]. - The total cash and cash equivalents increased by 423.88% to ¥1,292,091,664.07 from ¥246,638,671.00, reflecting improved liquidity[23]. Research and Development - Research and development expenses rose by 19.64% to ¥150,222,277.92 from ¥125,557,702.32, indicating a commitment to innovation[23]. - The company is committed to innovation-driven development, focusing on the R&D of drugs for critical diseases such as tumors and autoimmune diseases[18]. - The company has established a strong R&D platform with multiple laboratories to support the development of blood products, vaccines, and gene-engineered products, ensuring a robust innovation pipeline[19]. Market and Product Development - The company specializes in blood products, vaccines, and biopharmaceuticals, with a diverse range of 11 blood product varieties and 34 specifications[15]. - The company is focused on expanding its market presence and enhancing its product offerings in the biopharmaceutical sector[15]. - The company has launched several vaccines, including seasonal flu and recombinant hepatitis B vaccines[15]. Government Subsidies and Income - The company reported a significant increase in government subsidies, contributing to non-operating income[13]. - Government subsidies are classified into asset-related and income-related subsidies, with the former used for acquiring or constructing long-term assets[191]. Risks and Compliance - The company faces potential risks related to product safety, regulatory compliance, and rising raw material costs, which could impact profit margins[37][38]. - The company emphasizes quality control and has implemented a comprehensive quality assurance system to mitigate industry risks[37]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - A total of 4,122,300 restricted shares were unlocked for 111 eligible participants as part of the 2018 restricted stock incentive plan[43]. - The company’s top three shareholders are identified as acting in concert, with a combined holding of approximately 46.09%[65]. Financial Reporting and Compliance - The company's financial report for the first half of 2022 has not been audited[69]. - The financial statements are prepared based on actual transactions and in accordance with the accounting standards issued by the Ministry of Finance[99]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its ability to continue operations[100].

Financial Performance - The company's operating revenue for 2021 was ¥4,436,200,125.41, a decrease of 11.69% compared to 2020[12]. - The net profit attributable to shareholders for 2021 was ¥1,298,897,164.35, down 19.48% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥1,201,139,755.38, reflecting an 18.71% decrease year-over-year[12]. - The basic earnings per share for 2021 were ¥0.7133, down 19.61% from 2020[12]. - The diluted earnings per share for 2021 were ¥0.7094, a decrease of 19.95% compared to the previous year[12]. - The total operating revenue for 2021 was ¥4,436,200,125.41, a decrease of 11.69% compared to ¥5,023,206,263.40 in 2020[26]. - The operating profit was CNY 1,696,416,227.72, down 21.12% compared to the previous year[20]. - Blood products contributed ¥2,597,779,501.25, accounting for 58.56% of total revenue, with a slight increase of 0.25% year-on-year[26]. - Vaccine products generated ¥1,824,557,525.53, representing 41.13% of total revenue, showing a significant decline of 24.63% from the previous year[26]. Cash Flow and Assets - The net cash flow from operating activities increased by 8.09% to ¥1,432,495,972.60 in 2021[12]. - The cash and cash equivalents at the end of 2021 amounted to ¥692,537,541.18, representing 6.00% of total assets, a decrease of 4.34% from the beginning of the year[46]. - The total assets at the end of 2021 reached ¥11,537,237,136.45, a 14.93% increase from the end of 2020[12]. - The total liabilities amounted to CNY 2.47 billion in 2021, compared to CNY 1.94 billion in 2020, representing an increase of around 27.5%[148]. - The total equity attributable to shareholders increased to CNY 8.34 billion in 2021, up from CNY 7.53 billion in 2020, reflecting a growth of approximately 10.8%[149]. Research and Development - The company has established a strong research and development platform, focusing on blood products, vaccines, and gene-engineered products[26]. - The company aims to develop innovative drugs for critical diseases such as cancer and autoimmune diseases, ensuring safety and accessibility for patients[22]. - The company has 7 monoclonal antibody products in clinical trials, including Adalimumab and Trastuzumab, with several in Phase III trials[20]. - Research and development expenses increased by 18.96% to 253,634,720.97 yuan in 2021 compared to 2020[39]. - The number of R&D personnel rose by 6.37% to 701 in 2021, with the proportion of R&D staff increasing to 23.95% from 22.83%[41]. Market and Product Development - The monoclonal antibody market in China is expected to grow to CNY 194.5 billion by 2025, with a CAGR of 36.5% from 2020 to 2025[20]. - The company is focusing on expanding its vaccine product line and enhancing its competitive edge in the market[19]. - The company is developing several new products, including a recombinant human COVID-19 vaccine and various immunoglobulin products, which are expected to enhance product variety and profit growth[41]. - The company is conducting clinical research on multiple new vaccines, including a four-valent influenza virus vaccine and a rabies vaccine, aimed at increasing market share and competitiveness[41]. Governance and Compliance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring strong independence and standardized information disclosure[62]. - The board of directors consists of various specialized committees, including the strategy, nomination, audit, and compensation committees, enhancing operational efficiency[64]. - The company has implemented a transparent performance evaluation and incentive mechanism for its senior management, aiming to attract and retain talent[64]. - The company has a robust investor relations management system to ensure equal treatment of all shareholders, particularly minority shareholders[63]. Risk Management - The company has detailed potential risks that may adversely affect its future development strategy and operational goals in the report[3]. - The company faces risks related to the rising costs of raw plasma and increased competition, which may impact profit margins[58]. - The company is committed to maintaining a high-quality assurance system to mitigate risks associated with product safety and potential adverse reactions[56]. Shareholder and Dividend Policy - The company reported a profit distribution plan to distribute a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, totaling 1,824,366,726 RMB[3]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[89]. - The company plans to enhance its core competitiveness by accelerating the development of innovative drugs and biosimilars[26]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions and has successfully passed energy management system certification[100]. - There were no environmental penalties or violations reported during the reporting period[100]. - The company actively respects and protects the rights of all stakeholders, including shareholders, employees, and society[64].